Key facts
- It has raised $29.5M.
- Notable investors include Beijing State-owned Capital Operation and Management, Shun Xi Fund, Saiying Capital, Zhangzhou Pien Tze Huang Investment Management, Ascentage Pharma — 13 tracked in total.
- Status: Privately Held (backing).
Investors
13+- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Inhal Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Inhal Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Inhal Pharma
Developer of a dry powder inhalation platform designed to advance formulation development, inhaler design, and inhaled drug manufacturing. The company offers integrated development capabilities, a portfolio of inhaled health products, generic dry powder inhalers, and emerging inhaled therapeutics, enabling patients with respiratory and systemic conditions to access practical and effective inhaled treatments.
- Sector
- Healthcare
- HQ
- Ningbo City, China
- Founded
- 2020
- Employees
- 80
- Website
- inhalpharma.com/
- Ownership
- Privately Held (backing)
Inhal Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Inhal Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Inhal Pharma in its N-PORT filings yet. We sweep new filings monthly.